NDC 71335-1077

Acyclovir

Acyclovir

Acyclovir is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Bryant Ranch Prepack. The primary component is Acyclovir.

Product ID71335-1077_1e1ab04a-ed67-4b12-a671-92b86ac9153e
NDC71335-1077
Product TypeHuman Prescription Drug
Proprietary NameAcyclovir
Generic NameAcyclovir
Dosage FormTablet
Route of AdministrationORAL
Marketing Start Date2018-05-04
Marketing CategoryANDA / ANDA
Application NumberANDA210401
Labeler NameBryant Ranch Prepack
Substance NameACYCLOVIR
Active Ingredient Strength400 mg/1
Pharm ClassesDNA Polymerase Inhibitors [MoA], Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Nucleoside Analog [EXT]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 71335-1077-0

120 TABLET in 1 BOTTLE (71335-1077-0)
Marketing Start Date2019-02-08
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 71335-1077-5 [71335107705]

Acyclovir TABLET
Marketing CategoryANDA
Application NumberANDA210401
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-30

NDC 71335-1077-8 [71335107708]

Acyclovir TABLET
Marketing CategoryANDA
Application NumberANDA210401
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-30

NDC 71335-1077-2 [71335107702]

Acyclovir TABLET
Marketing CategoryANDA
Application NumberANDA210401
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-30

NDC 71335-1077-6 [71335107706]

Acyclovir TABLET
Marketing CategoryANDA
Application NumberANDA210401
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-30

NDC 71335-1077-7 [71335107707]

Acyclovir TABLET
Marketing CategoryANDA
Application NumberANDA210401
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-30

NDC 71335-1077-1 [71335107701]

Acyclovir TABLET
Marketing CategoryANDA
Application NumberANDA210401
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-30

NDC 71335-1077-9 [71335107709]

Acyclovir TABLET
Marketing CategoryANDA
Application NumberANDA210401
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-30

NDC 71335-1077-4 [71335107704]

Acyclovir TABLET
Marketing CategoryANDA
Application NumberANDA210401
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-30

NDC 71335-1077-3 [71335107703]

Acyclovir TABLET
Marketing CategoryANDA
Application NumberANDA210401
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-30

NDC 71335-1077-0 [71335107700]

Acyclovir TABLET
Marketing CategoryANDA
Application NumberANDA210401
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-01-30

Drug Details

Active Ingredients

IngredientStrength
ACYCLOVIR400 mg/1

OpenFDA Data

SPL SET ID:1e1ab04a-ed67-4b12-a671-92b86ac9153e
Manufacturer
UNII

Pharmacological Class

  • DNA Polymerase Inhibitors [MoA]
  • Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
  • Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
  • Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
  • Nucleoside Analog [EXT]
  • DNA Polymerase Inhibitors [MoA]
  • Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
  • Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
  • Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
  • Nucleoside Analog [EXT]

NDC Crossover Matching brand name "Acyclovir" or generic name "Acyclovir"

NDCBrand NameGeneric Name
0093-3630Acycloviracyclovir
0093-8940AcyclovirAcyclovir
0093-8943AcyclovirAcyclovir
0093-8947AcyclovirAcyclovir
0143-9657AcyclovirAcyclovir
0143-9658AcyclovirAcyclovir
0168-0825acycloviracyclovir
0378-8700Acycloviracyclovir
0378-8712AcyclovirAcyclovir
0440-6030AcyclovirAcyclovir
0440-7033acycloviracyclovir
0472-0082AcyclovirAcyclovir
0591-1159Acycloviracyclovir
0713-0630AcyclovirAcyclovir
0904-5789ACYCLOVIRACYCLOVIR
0904-5790acycloviracyclovir
10544-039Acycloviracyclovir
10544-089Acycloviracyclovir
10544-101AcyclovirAcyclovir
68071-1841AcyclovirAcyclovir
68071-3155AcyclovirAcyclovir
68071-3222AcyclovirAcyclovir
68071-4528AcyclovirAcyclovir
68071-4559acycloviracyclovir
68071-4345AcyclovirAcyclovir
68084-109AcyclovirAcyclovir
68084-108AcyclovirAcyclovir
68071-4790AcyclovirAcyclovir
68071-4799AcyclovirAcyclovir
68084-107ACYCLOVIRACYCLOVIR
68382-125acycloviracyclovir
68382-049acycloviracyclovir
68382-048acycloviracyclovir
68382-668acycloviracyclovir
68382-126acycloviracyclovir
68382-792acycloviracyclovir
68382-791acycloviracyclovir
68382-992acycloviracyclovir
68462-746acycloviracyclovir
68788-6360acycloviracyclovir
68788-0505AcyclovirAcyclovir
68788-0504AcyclovirAcyclovir
68788-0715AcyclovirAcyclovir
68788-8989acycloviracyclovir
68788-6827ACYCLOVIRACYCLOVIR
68788-7382acycloviracyclovir
68788-7378acycloviracyclovir
68788-9783AcyclovirAcyclovir
68788-7342AcyclovirAcyclovir
68788-9690AcyclovirAcyclovir

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.